NCT02491281View on ClinicalTrials.gov

First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 16, 2015

Primary Completion Date

February 7, 2018

Study Completion Date

March 6, 2018

Conditions
Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Interventions
DRUG

LNA043

ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery

DRUG

Placebo

ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery

Trial Locations (1)

85053

Novartis Investigative Site, Phoenix

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY